Lisa A Cannon-Albright

Title: Innovations in Cancer Detection and Therapy by Lisa A Cannon-Albright

Introduction

Lisa A Cannon-Albright is a prominent inventor based in Salt Lake City, UT (US). She has made significant contributions to the field of cancer research, particularly in the detection and therapy of cancers related to mutations in the Multiple Tumor Suppressor (MTS) gene. With a total of 2 patents, her work has the potential to impact the diagnosis and treatment of various cancers.

Latest Patents

Cannon-Albright's latest patents focus on methods for detecting predisposition to cancer at the MTS gene. The first patent relates to somatic mutations in the MTS gene in human cancers and their use in diagnosis and prognosis. It also addresses germ line mutations in the MTS gene and their implications for diagnosing predisposition to several types of cancer, including melanoma, leukemia, and breast cancer. Additionally, the invention discusses therapies for cancers with MTS gene mutations, including gene therapy and drug screening for cancer treatment.

Career Highlights

Throughout her career, Lisa A Cannon-Albright has worked with esteemed organizations such as the University of Utah Research Foundation and Myriad Genetics, Inc. Her research has been pivotal in advancing the understanding of genetic factors in cancer predisposition and therapy.

Collaborations

Cannon-Albright has collaborated with notable professionals in her field, including Mark H Skolnick and Alexander Kamb. These collaborations have further enriched her research and innovations in cancer detection and treatment.

Conclusion

Lisa A Cannon-Albright's contributions to cancer research through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in cancer diagnosis and therapy.